Rett syndrome is an X-linked autism spectrum disorder. The disease is characterized in most cases by mutation of the MECP2 gene, which encodes a methyl-CpG-binding protein 125 . Although MECP2 is expressed in many tissues, the disease is generally attributed to a primary neuronal dysfunction 6 . However, as shown recently, glia, specifically astrocytes, also contribute to Rett pathophysiology. Here we examine the role of another form of glia, microglia, in a murine model of Rett syndrome. Transplantation of wild-type bone marrow into irradiation-conditioned Mecp2-null hosts resulted in engraftment of brain parenchyma by bone-marrow-derived myeloid cells of microglial phenotype, and arrest of disease development. However, when cranial irradiation was blocked by lead shield, and microglial engraftment was prevented, disease was not arrested. Similarly, targeted expression of MECP2 in myeloid cells, driven by Lysm cre on an Mecp2-null background, markedly attenuated disease symptoms. Thus, through multiple approaches, wild-type Mecp2expressing microglia within the context of an Mecp2-null male mouse arrested numerous facets of disease pathology: lifespan was increased, breathing patterns were normalized, apnoeas were reduced, body weight was increased to near that of wild type, and locomotor activity was improved. Mecp2 1/2 females also showed significant improvements as a result of wild-type microglial engraftment. These benefits mediated by wild-type microglia, however, were diminished when phagocytic activity was inhibited pharmacologically by using annexin V to block phosphatydilserine residues on apoptotic targets, thus preventing recognition and engulfment by tissue-resident phagocytes. These results suggest the importance of microglial phagocytic activity in Rett syndrome. Our data implicate microglia as major players in the pathophysiology of this devastating disorder, and suggest that bone marrow transplantation might offer a feasible therapeutic approach for it.
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The role of glia in Rett syndrome has recently been recognized 729 . Mecp2-null astrocytes were unable to support the normal dendritic ramification of wild-type neurons growing in culture 7 , and expression of wild-type MECP2 protein in astrocytes of Mecp2-null hosts dramatically ameliorated disease pathology 9 . Mecp2-null microglia were reported to be toxic to neurons in vitro through production of high levels of glutamate 10 .
Microglia, the brain-resident macrophages, are of haematopoietic origin 11 . Still, the idea of repopulation of brain microglia from bonemarrow-derived cells in adult mice under normal physiological conditions is controversial 12 . However, when bone marrow transplantation is preceded by irradiation-mediated immune ablation, bone-marrow-derived cells with microglia-like morphology and phenotype (expressing low levels of CD45 and high levels of CD11b) are found in the brain 13, 14 . Microglia have received increasing attention in the pathophysiology of several neurodegenerative and neuropsychiatric diseases 14218 .
We first studied microglial function in the context of Mecp2 2/y male mice. Males possess a single mutant X chromosome, and thus manifest a severe phenotype that includes markedly retarded growth, apnoeas, tremor, impaired gait and locomotor function, and a postnatal life expectancy of approximately 8 weeks 4, 19 (Fig. 1a, b and Supplementary Movie 1).
To address the role of hematopoietically derived cells in the pathophysiology of Rett, Mecp2 2/y (Mecp2 tm1.1Jae and Mecp2 tm2Bird ) mice were subjected to lethal split-dose irradiation at postnatal day (P)28 (the approximate age at which neurological signs appear 4 ). Mice were then injected intravenously with syngeneic bone marrow from C57Bl/6J mice ubiquitously expressing green fluorescent protein (GFP). Control groups were injected with autologous (Mecp2 2/y ) bone marrow, or left naive. Surprisingly, the lifespan of Mecp2-null recipients of wild-type bone marrow (wild type R Mecp2 2/y ) was significantly extended compared with Mecp2 2/y mice receiving autologous bone marrow (Mecp2 2/y R Mecp2 2/y ) or to naive Mecp2 2/y mice ( Fig. 1b and Supplementary Movie 2). Our oldest living wild-type R Mecp2 2/y mice were over 48 weeks of age (Supplementary Movie 3); most experimental mice were euthanized at the age of ,16 weeks for tissue analysis.
Although Mecp2 2/y mice on the C57Bl/6J background are undersized 4, 19 , within 4 weeks of transplantation, wild-type R Mecp2 2/y (but not Mecp2 2/y R Mecp2 2/y ) mice approached the size of wild-type littermates ( Fig. 1c, d ). Wild-type R Mecp2 2/y mice also exhibited an increase in brain weight ( Fig. 1e , f), which was probably caused by general growth of the mouse, because the reduced soma size characteristic of Mecp2-null neurons was not changed by bone marrow transplantation ( Fig. 1g , h) and the brain to body weight ratio was normalized ( Supplementary Fig. 1a ). Spleens of Mecp2 2/y mice were also smaller than normal and their size normalized after transplantation ( Supplementary Fig. 1b-d) .
Growth retardation is a characteristic feature of Rett pathology. Along these lines, treatment with insulin-like growth factor (IGF)-1 benefits survival and behavioural outcomes in Mecp2-null mice 20 . Indeed, peripheral macrophages from wild-type mice expressed significantly higher levels of IGF-1 in vitro in response to immunological stimuli than macrophages from Mecp2-null (Mecp2 tm1.1Jae/y ) mice ( Supplementary  Fig. 2) ; this difference may contribute to the increased body growth seen in Mecp2-null mice after bone marrow transplantation.
The general appearance of wild-type R Mecp2 2/y mice was improved compared with that of naive Mecp2 2/y or Mecp2 2/y R Mecp2 2/y mice. The severe involuntary tremors normally seen in mutant mice were absent following wild-type bone marrow transplantation ( Fig. 2a ), and gait was improved. Interestingly, no detectable benefit on hindlimb clasping phenotype was observed.
Breathing irregularities and apnoeas are cardinal signs of Rett syndrome. We used whole-body plethysmography to compare the breathing patterns of Mecp2 2/y mice with or without bone marrow transplantation to those of control mice (Fig. 2b ). As expected, Mecp2 2/y mice developed apnoeas progressively with age (data not shown). However, wild type R Mecp2 2/y exhibited significantly reduced apnoeas and fewer breathing irregularities than either naive Mecp2 2/y or Mecp2 2/y R Mecp2 2/y mice ( Fig. 2c, d ). Wild-type R Mecp2 2/y mice also displayed significantly increased mobility in the open field compared with naive Mecp2 2/y or Mecp2 2/y R Mecp2 2/y mice ( Fig. 2e, f) .
We also performed bone marrow transplantation in heterozygous female mice at 2 months of age, and animals were examined at 9 months. The disease in Mecp2 1/2 mice develops slowly, with behavioural abnormalities becoming clear at 4-6 months of age. Weights of treated Mecp2 1/2 mice were comparable to wild-type controls (Fig. 2g ). Moreover, there was significant improvement in motor function, as examined on rotarod (Fig. 2h ), and time spent in the centre of the open field arena was significantly increased (Fig. 2i ).
Apnoeas in bone marrow transplanted mice were reduced ( Fig. 2j ) and their overall breathing patterns were improved compared with their non-treated controls (Fig. 2k ). The peripheral immune system of Mecp2 2/y hosts was repopulated by donor bone marrow ( Supplementary Fig. 3a ). Additionally, it has been previously shown that bone marrow transplantation after wholebody irradiation results in engraftment of microglia-like myeloid cells into the brain parenchyma 13 . Indeed, GFP 1 cells in the parenchyma of bone marrow transplanted mice expressed CD11b ( Fig. 3a) but not GFAP or NeuN (data not shown). Twelve weeks after bone marrow transplantation, mice were perfused and their brains dissected into 
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sub-areas, prepared in single-cell suspensions and analysed using flow cytometry to determine percentages of bone-marrow-derived (GFP 1 ) cells in the haematopoietic (CD45 1 ) cell fractions in the brain ( Supplementary Fig. 3b, c) .
Interestingly, in mice in which bone marrow transplantation was performed later (P40 or P45), only slight improvements in disease pathology were observed ( Supplementary Fig. 4a ). No microglial engraftment was evident, although substantial numbers of GFP 1 cells were found in the meningeal spaces ( Supplementary Fig. 4b ). These results may suggest that when disease progression is faster than microglial engraftment, full rescue cannot be achieved. The moderate results observed, however, may have been due to a yet-unknown mechanism, perhaps through soluble factors produced by meningeal immune cells, or peripherally-expressed IGF-1 ( Supplementary Fig. 2 ). When bone marrow transplantation was performed at P2 without irradiation, minimal peripheral chimaerism was achieved without detectable microglial engraftment and no lifespan extension was observed ( Supplementary Fig. 4a, c) .
Newly engrafted microglia expressed detectable levels of wild-type Mecp2 (data not shown) but nearby cells did not show any Mecp2 labelling, arguing against the possibility of protein or messenger RNA transfer from engrafted microglia into nearby cells as an underlying mechanism for the beneficial effect of bone marrow transplantation.
To substantiate the specific role of microglia in bone marrow transplantation-mediated disease arrest, we repeated transplantation experiments, again at P28, but with the addition of lead shielding to block cranial irradiation, which results in repopulation of peripheral immunity (Fig. 3b, c) but no parenchymal engraftment (Fig. 3d) , supporting previously published work 13, 18 . Disease was not arrested in 'head-covered' mice ( Fig. 3e ), suggesting that peripheral immune reconstitution without microglial engraftment is insufficient to arrest pathology in Mecp2 2/y mice.
To substantiate further the role of myeloid cells in arrest of Rett pathology, we used a genetic approach. We employed the widely used Lysm Cre mouse-which results in a high degree of recombination in myeloid cells, granulocytes and in significant numbers of microglia 21223 -in cross with Mecp2 lox-stop mice. Male progeny, Mecp2 lox-stop/y Lysm cre , express wild-type Mecp2 in myeloid cells on an otherwise Mecp2-null background. These animals exhibited improvements in overall appearance and growth (Fig. 3f, g and Supplementary Movie 4) and their lifespans were significantly increased (Fig. 3h ). The oldest Mecp2 lox-stop/y Lysm cre animals were 31 weeks of age, with survival of 100%; n 5 6 mice per group. Apnoeas and interbreath irregularity of these mice were also significantly reduced compared with control mice (Fig. 3i, j) , and their open field activity was not significantly different from wild-type counterparts (Fig. 3k) . These results cannot be interpreted by cre leakiness, because no cre-mediated recombination was evident in either astrocytes or neurons in Lysm cre crossed to a reporter strain (data not shown), in line with previous publications 22, 23 .
Microglia from Mecp2-null mice were deficient in their response to immunological stimuli ( Supplementary Fig. 5 ) and in phagocytic capacity, as examined by feeding cultured microglia with pre-labelled ultraviolet-irradiated neural progenitor cells, used as apoptotic targets 24 (Fig. 4a-c 
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bone marrow, only GFP 1 parenchymal cells were consistently found containing cleaved caspase-3-positive debris within lysosomes (Fig. 4d ). It has been previously shown that annexin V (a protein that binds phosphatidylserine on apoptotic cells and inhibits engulfment) injected intravenously can reach the central nervous system 25 . Moreover, we have recently shown that intravenous injection of annexin V results in substantial blockade of phagocytic activity in the brain 24 . Indeed, treatment of wild-type mice with annexin V resulted in significant accumulation of terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labelling (TUNEL) 1 fragments ( Supplementary Fig. 6 ).
We attempted to inhibit brain phagocyte activity pharmacologically in Mecp2 lox-stop/y Lysm cre mice and compare disease progression with controls. Long-term treatment of Mecp2 lox-stop/y Lysm cre mice with annexin V abolished the amelioration of the disease normally seen in these mice ( Fig. 4e-g) . Wild-type mice treated with annexin V were not significantly affected. This is probably because, unlike in Mecp2 lox-stop/y Lysm cre mice, neurons and astrocytes in wild-type mice are fully functional, expressing wild-type MECP2. It is conceivable, however, that a longer treatment of wild-type mice with annexin V might result in neurological pathology. Overall, these results suggest active engagement of wild-type microglia in clearance of apoptotic cells or cell remnants within the context of otherwise Mecp2-null brain-a task that probably cannot be sufficiently performed by Mecp2-null microglia.
Neuropathologists have observed gliosis and cell loss in the cerebellum of deceased patients who had Rett syndrome 26 , but this work has not received much attention, presumably because the disease is generally considered non-neurodegenerative. Our results do not claim that neurodegeneration underlies the pathology of the disease. Rather, they suggest that Mecp2-null microglia, deficient in phagocytic function, may be unable to keep pace in clearing debris left behind from the normal process of neural cell death or membrane shedding. This, in turn, would lead to a crowded and sub-optimal central nervous system milieu within which neurons, already challenged by loss of Mecp2, might be further impaired in function. The inability of Mecp2-null microglia to clear debris as effectively as wild-type microglia has the potential to contribute to the underlying neuropathology and/or the time course of appearance of symptoms in Mecp2-null mice 4, 27 .
Future studies should be aimed at understanding the connections between glial phagocytic activity and neuronal function, and possible interactions between microglia and astrocytes in the pathology of Rett syndrome. Phagocytic activity per se is almost certainly just one aspect of glial involvement in the pathophysiology of the disease. It is conceivable that glia, including astrocytes-which are also capable phagocytes 28 -release soluble factors in connection with their own phagocytic activity, in turn benefiting neuronal function. Therefore, removal of debris itself may not be as primarily relevant to disease progression as a secondary response of glia to the phagocytic process. Accordingly, inhibition of phagocytosis might result in exacerbation of pathology of the disease through these as yet unknown processes, even in the absence of deposits of easily observable cellular debris.
Our present findings support previous publications describing the potential for clinical treatment of Rett pathology 6, 29 , while also suggesting the possibility of achieving this goal through augmentation or repopulation of brain phagocytes, or improvement of their phagocytic activity. These results open the possibility for a new approach in the amelioration of the pathology of Rett syndrome.
METHODS SUMMARY
Animals. Male and female C57Bl/6-Tg(UBC-GFP)30Scha/J, C57Bl/6J, B6.129P2(C)Mecp2 tm1.1Bird /J, B6.129P2-Lyz2 tm1(cre)Ifo /J (Lysm cre ), B6.129P2-Mecp2 tm2Bird /J, Mecp2 lox-stop/y and C57BL/6J mice were purchased from Jackson Laboratories; B6.Cg-Mecp2 tm1.1Jae/Mmcd mice were a gift from A. Pieper and maintained in our laboratory on C57Bl/6J background. All procedures complied with regulations of the Institutional Animal Care and Use Committee at The University of Virginia. Irradiation and bone marrow transfer. Four-week-old mice were subjected to lethal split-dose c-irradiation (300 rad followed 48 h later by 950 rad). Four hours after the second irradiation, mice were injected with 5 3 10 6 bone marrow cells. After irradiation, mice were kept on drinking water fortified with sulphamethoxazole for 2 weeks to limit infection by opportunistic pathogens. (right) microglia incubated for 2 or 5 h with fluorescently labelled ultraviolet-irradiated neural progenitor cells and stained with anti-CD11b. Scale bar, 50 mm. c, Bar graphs comparing surface area of ultraviolet-irradiated neural progenitor cells (NPC) to total surface area (mean 6 s.e.m.) of wild-type or Mecp2 2/y microglia (**P , 0.01; ***P , 0.001; one-way ANOVA; representative experiment shown out of three independently performed). d, Representative micrograph of phagocytosing microglia in situ containing cleaved caspase-3 debris co-localized with lysosomal marker, Lamp-1. Scale bar, 50 mm. e-g, Mecp2 lox-stop/y Lysm Cre mice and the appropriate controls were treated with annexin V to inhibit phagocytic activity pharmacologically. e, Weights (mean 6 s.e.m.) of Mecp2 1/y Lysm Cre , Mecp2 lox-stop/y Lysm Cre , Mecp2 lox-stop/y , Mecp2 1/y Lysm Cre mice treated with annexin V and Mecp2 lox-stop/y Lysm Cre mice treated with annexin V are shown at the end point for Mecp2 lox-stop/y and Mecp2 lox-stop/y Lysm Cre treated with annexin V groups (,P63). f, Neurological scores (mean 6 s.e.m.) at P56 are presented (***P , 0.001; one-way ANOVA; n 5 at least seven mice per group; Bonferroni post hoc test was used for individual comparisons). g, Distance travelled (mean 6 s.e.m.) in an open field by mice from all the above groups (***P , 0.001; one-way ANOVA, n 5 5 mice per group; Bonferroni post hoc test was used for individual comparisons).
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